sexta-feira, 13 de novembro de 2026
PesquisarExplore
Via News Knowledge File

Datavault AI Inc.

organization80% conf.·synced Aug 13, 2026

Publicly traded company on Nasdaq

30
sourced metrics
545
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
0.7212USD
Trading Volume
16599924shares
Market Cap
1200000000USD
Apr 27, 2026source
Revenue
10000000000USD
Apr 27, 2026source
Cash
200000000USD
Apr 27, 2026source
Current Assets
142.9USD
Mar 19, 2026source
Current Liabilities
26.9USD
Mar 19, 2026source
Long Term Debt
0USD
Mar 19, 2026source
Net Income
0.661USD
Mar 19, 2026source
Operating Profit
4.2USD
Mar 19, 2026source
Working Capital
116USD
Mar 19, 2026source
Gross Margin
78percent
Mar 19, 2026source
Dividend Record Date
2026-01-07date
Jan 7, 2026source
New Patents Published
9patents
Dec 31, 2025source
New Patents Issued
9patents
Dec 31, 2025source
Patent Portfolio
63patents
Dec 31, 2025source
Patent Count
63patents
Dec 31, 2025⚠ sources conflictsource
Warrant Strike Price
5.00USD
Dec 30, 2025source

Stated objectives

Drive breakthroughs in quantum computing and AI through Georgia facility and university partnerships

source
stated

Strengthen European collaboration in tokenized assets and AI monetization through London embassy

source
stated

Democratize access to art, luxury assets, and high-value collectibles through 1571 platform

source
stated

Complete Philadelphia headquarters relocation and operate fully throughout 2026 campaign

source
by 2026-01-01 00:00:00stated

Expand VerifyU identity verification platform and ADIO engagement technology from education and corporate sectors into entertainment and nightlife sectors

source
stated

Generate annual recurring revenue (ARR) from each club deploying Joke Token through AI agent tracking, licensing, ticketholder digital twins, and structured licensing agreements

source
stated

Enhance and elevate the profile of Dream Bowl XIV through AI integration and digital asset innovation

source
by 2026-01-11 00:00:00stated

Transform traditional commodity handling by creating unified transaction ledger for mineral verification, documentation, and global trade integration with accuracy and traceability across all stages

source
stated

Enable digital records for minerals to facilitate lending, collateralization, and cross-border trade using documented digital assets

source
stated

Use MTB partnership as practical framework demonstrating how physical assets evolve into documented, traceable digital assets and replicate model for future mineral mining operations

source
stated

Relationship graph · 545 connections

Developed by
219
headquartered in
38
Employs
32
subsidiary of
20
listed on
18
Supplies to
17
contracted by
16
Partnered with
16
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com